15% OFF BPC-157 500 mcg – 100 pcs per bottle (Research Use Only)
BPC-157, a synthetic pentadecapeptide studied in preclinical tissue-repair and angiogenesis research. 500mcg × 100 capsules, ≥98% purity (supplier specification). Supplied for laboratory research and identification purposes only.
Availability: In stock
3–4 vials — 5% off · 5–9 vials — 10% off · 10+ vials — 15% off
Applied automatically in the cart. Combines with a discount code up to 20% off in total, and stacks on top of the subscription discount.
Research Disclaimer: All products currently listed on this site are for research purposes only.
- Studied in tendon, ligament and joint models for effects on connective-tissue repair signalling
- Investigated in animal models for effects on intestinal epithelial integrity and permeability
- Studied for angiogenesis, nerve regeneration and repair signalling beyond the injury site
- No hormonal-axis activity documented in the published literature
- Among the more extensively published compounds in the preclinical repair literature
Research FAQ
What is BPC-157 studied for?
BPC-157 is studied for localized tissue repair — tendon, ligament, bone, and gut — largely through VEGFR2-driven angiogenesis. Sold for research use only.
How does BPC-157 differ from TB-500?
BPC-157 is studied for localized structural repair via angiogenesis, while TB-500 is studied for systemic cell migration via actin regulation. They are complementary and often researched together.
Mechanism of Action
BPC-157 (Body Protection Compound-157) is a pentadecapeptide derived from a protein found in gastric juice. In preclinical models it is associated with angiogenesis via upregulation of VEGF pathways, with collagen production in tendon and ligament tissue, and with nitric oxide synthesis affecting inflammatory signalling and vascular tone. Published work spans musculoskeletal, neurological and vascular tissue models as well as the gut.
Research Overview
Animal-model research reports accelerated healing of Achilles tendon transections, ligament ruptures and muscle tears, with histological evidence of improved collagen organisation versus untreated controls. Gut-directed studies report restoration of intestinal epithelial integrity and reduced NSAID-induced ulceration. More than 80 preclinical studies have been published, spanning musculoskeletal, neurological and gastrointestinal models. Human evidence is not established.
Research & Stack Notes
Oral routes appear in gut-directed research designs. The published literature also examines BPC-157 alongside TB-500, which acts through actin sequestration rather than VEGF signalling. No interactions with GLP-1, cognitive or longevity compounds are documented in that literature.
Educational purposes only. Research use. Not evaluated by the FDA.
Overview
BPC-157, TB-500 & GHK-Cu: What’s the Difference?
Six related products, in two formats. Here’s what’s actually in each one.
| Product | Contains | Format | Price |
|---|---|---|---|
| BPC-157 (injectable) | BPC-157 only | Injectable vial, 10mg | $56.00 |
| BPC-157 (capsules) | BPC-157 only | 100 capsules, 500mcg each | $155.00 |
| TB-500 | TB-500 only | Injectable vial, 10mg | $72.00 |
| BPC-157 + TB-500 | BPC-157 + TB-500 (5mg + 5mg) | Injectable vial, 10mg total | $69.00 |
| BPC + TB Capsules | BPC-157 + TB-500 (500mcg + 500mcg) | 100 capsules, 1,000mcg total each | $94.05 |
| GLOW-70 | GHK-Cu + TB-500 + BPC-157 (50mg + 10mg + 10mg) | Injectable vial | $112.00 |
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide with an extensive published preclinical research profile spanning gastrointestinal biology, musculoskeletal repair modeling, neuroscience, and angiogenesis research. Derived from a partial sequence of a gastroprotective protein described in the peer-reviewed literature, BPC-157 is notable for its acid-stable properties, which are of interest in studies examining peptide pharmacokinetics and in vitro stability under gastrointestinal simulation conditions.
What It Is
BPC-157 is a synthetic pentadecapeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val and a molecular weight of approximately 1,419 Da. It represents a partial sequence of a body protection compound described in the peer-reviewed literature and is notable for its acid-stable properties in in vitro pharmacokinetic assay conditions.
Research Spotlight
More than 100 peer-reviewed preclinical studies have investigated BPC-157 across a range of biological models. Gastrointestinal research has focused on mucosal integrity, investigating interactions with the nitric oxide (NO) signaling pathway and cytoprotective mechanisms in rodent ulceration and inflammatory bowel models. Musculoskeletal studies have placed BPC-157 in tendon transection, ligament tear, and bone repair models, measuring biomechanical and histological endpoints across multi-week time courses. Published neuroscience research has documented BPC-157’s interactions with dopaminergic, serotonergic, and GABAergic systems in rodent behavioral and pharmacological models. Angiogenesis research has examined VEGF expression and capillary network formation markers in wound and tissue repair models. BPC-157 has also been studied in models of organ and tissue damage, with published investigations examining hepatic, renal, and vascular preparations.
Key Research Applications
- Gastrointestinal mucosal protection and intestinal permeability modeling
- Tendon, ligament, bone, and musculoskeletal tissue repair studies
- Nitric oxide pathway and vasculogenic signaling investigations
- Dopaminergic, serotonergic, and GABAergic system modulation research
- VEGF-mediated angiogenesis and wound healing marker studies
- Organ-protective mechanism research (hepatic, renal, cardiovascular models)
- In vitro acid-stability and peptide pharmacokinetic characterization studies
- Inflammatory response modulation in gastrointestinal and systemic models
For laboratory research use only. Not intended for human or veterinary use, medical diagnosis, treatment, or prevention of any disease or condition. This product has not been evaluated by the FDA or any regulatory agency. Must be handled by qualified research personnel in a compliant laboratory setting.
Not sure which compounds fit your research? Browse the Research Hub →
Related research (educational)
- Overlapping Pathways in Circadian, Repair and Mitochondrial Biology
- BPC-157: The Recovery Compound
- Recovery & Repair Research Compounds: A Complete Guide
Regulatory Status Note
On July 23–24, 2026, FDA’s Pharmacy Compounding Advisory Committee reviewed whether BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon, and emideltide (DSIP) should be added to the 503A Bulks List for pharmacy compounding. The committee voted to recommend six of the seven; emideltide (DSIP) was not recommended. FDA’s own briefing documents had recommended against all seven.
A committee vote is a recommendation only. It does not constitute FDA approval, does not establish safety or effectiveness, and does not change the status of this product, which is sold strictly for research use. FDA must complete formal rulemaking before any substance is added to the list. Source: FDA Advisory Committee Calendar. Last reviewed: August 17, 2026.
Update — July 24, 2026: On July 23, the committee voted. BPC-157, KPV, and TB-500 each passed 8-6 with one abstention; MOTS-c passed 7-5 with two abstentions. The recommendation is non-binding — FDA is not required to follow it, must still issue a formal decision, and the process may require additional rulemaking before any compounding pharmacy could act on it. No peptide has been FDA-approved, and this update does not constitute or imply a therapeutic claim. Source: STAT News
At a Glance: Four Separate Questions
- Research status: Sold for research/laboratory use only, not as a consumer drug.
- Compounding status: An FDA advisory committee recommended possible inclusion on the 503A Bulks List (non-binding). FDA has not issued a final decision.
- FDA approval status: Not FDA-approved for any use.
- Evidence status: Preclinical/animal research on tissue and tendon repair; no completed human clinical trials have established safety or efficacy for any condition.
Last reviewed: August 9, 2026 — status unchanged (still an advisory committee recommendation; not final 503A inclusion or FDA approval). See our full explainer on these four categories.
Research Library
All BPC-157 formats in one place. Compare injectable vials, oral capsules and blend preparations — presentation, pricing and current lab testing status — on the BPC-157 product index. Research use only.
- Processing: Orders ship within 1–2 business days
- Domestic delivery: 3–5 business days via USPS Priority / UPS Ground
- Free shipping on orders over $100
- Temperature handling: Cold-chain packaging available on request for lyophilized peptides
- Tracking: Emailed automatically at time of dispatch
- Store lyophilized (dry) peptides at −4 °F for long-term stability
- Protect from light and moisture at all times
- Do not freeze
- Where the Storage row in the product specification above differs, follow the specification
Pairs Well With
Related research products
Reviews
There are no reviews yet.